# Sterilizing Effects of Novel Regimens Containing TB47, Clofazimine and Linezolid in a Murine Model of Tuberculosis

Wei Yu, [a,b,c,*] Yusuf Buhari, [a,b,c,*] Shuai Wang, [a,b,c] Xirong Tian, [a,b,d] H. M. Adnan Hameed, [a,b] Zhili Lu, [a,b] Gift Chiwala, [a,b,c] Md Shah Alam, [a,b,c] Gregory M. Cook, [f,g] Dmitry A. Maslov, [h] Nanshan Zhong, [b,e] Tianyu Zhang [a,b,c,#]

[a] State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), Guangzhou 510530, China

[b] Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), Guangzhou 510530, China

[c] University of Chinese Academy of Sciences (UCAS), Beijing 100049, China

[d] Institute of Physical Science and Information Technology, Anhui University, Hefei, 230601, China

[e] State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, The National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, China

[f] Department of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin, 9054, New Zealand

[g] Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland,

20 Private Bag, 92019, Auckland 1042, New Zealand

21 [h] Laboratory of Bacterial Genetics, Vavilov Institute of General Genetics, Russian
22 Academy of Sciences, Moscow, 119333, Russia

23 [*] These authors contributed equally to this work.

24 [#] Corresponding author: Tianyu Zhang

25 Tel: +86-20-32015270

26 E-mail: zhang_tianyu@gibh.ac.cn

27 **Running title:** Novel regimens for drug-resistant TB

28 **Keywords:** tuberculosis, cytochrome $bc_1$-$aa_3$ oxidase, TB47, murine model, drug
29 resistance

30

**ABSTRACT**

**Toxicity and inconvenience associated with the use of injectable drug-containing regimens for tuberculosis (TB) have made all-oral regimens a preferred alternative. Widespread resistance to fluoroquinolones and pyrazinamide makes it essential to identify new drug candidates and study their effects on current regimens for TB. TB47 is a pyrazolo[1,5-a]pyridine-3-carboxamide with powerful synergistic *in vitro* and *in vivo* activities against mycobacteria, especially with clofazimine. Here, we investigated the bactericidal and sterilizing activities of novel oral regimens containing TB47 + clofazimine + linezolid, and the potential roles of levofloxacin and/or pyrazinamide in such drug combinations. Using a well-established mouse model, we assessed the effect of these regimens on bacterial burden in the lung during treatment and relapse (4 months after stopping treatment + immunosuppression). Our findings indicate that the TB47 + clofazimine + linezolid + pyrazinamide, with/without levofloxacin, regimens had fast-acting (4 months) sterilizing activity and no relapse was observed. When pyrazinamide was excluded from the regimen, treatment times were longer (5-6 months) to achieve sterilizing conditions. We propose that TB47 + clofazimine + linezolid can form a highly sterilizing block for use as an alternative pan-TB regimen.**

54 **INTRODUCTION**

55 Although tuberculosis (TB) is a treatable infectious disease, in 2019, an estimated 10
56 million people developed active TB, with 1.2 million deaths as well as 208,000 deaths
57 among HIV/TB co-infected individuals (1). For patients with drug-susceptible TB,
58 standard treatment with the four powerful first-line anti-TB drugs results in acceptable
59 cure rates. Patients who are infected with strains resistant to at least rifampicin (RIF) and
60 isoniazid, called multidrug-resistant TB (MDR-TB), possess limited treatment
61 alternatives and are practically incurable by the standard first-line treatment.
62 Approximately 500,000 new cases of MDR-TB occur annually with a low treatment
63 success rate at ≤ 57% (1). It usually takes 9 - 12 months for regimens containing at least
64 4 - 6 drugs, including at least one injectable agent, to treat patients with MDR-TB (2).
65 More seriously for patients, extensively drug-resistant TB (XDR-TB) is MDR-TB plus
66 resistance to a fluoroquinolone (FQ) and an injectable agent, with an unacceptably low
67 treatment success rate of only ≤ 39% (3). Novel drugs and regimens to shorten and
68 improve MDR/XDR-TB treatment success are urgently needed. If such regimens do not
69 contain RIF and isoniazid, they may be applicable to both drug-susceptible and MDR-
70 TB. Furthermore, if injectable drugs and FQs are also not included in the combination,
71 such regimens may be useful for XDR-TB treatment. For instance, the recent FDA-
72 approved combination, BPaL (bedaquiline + pretomanid + linezolid), is a fully oral
73 regimen with relatively shorter course of treatment that has shown remarkably promising

74 clinical effect against both MDR- and XDR-TB with manageable side effects. More of
75 such regimens are desired to improve TB treatment.

76 TB47, a pyrazolo[1,5-a]pyridine-3-carboxamide, is a promising anti-mycobacterial
77 agent as its mechanism of action is not shared with other existing drugs (4). It can block
78 the cytochrome $bc_1$-$aa_3$ oxidase complex by targeting the QcrB subunit, thereby causing a
79 reduction in intracellular ATP and eventually inhibiting the growth of mycobacteria (5,6).
80 Although mono-therapy with TB47 is rather bacteriostatic than bactericidal in mouse TB
81 models due to rerouting of energy metabolism from QcrB to the cytochrome *bd* oxidase
82 (7,8), it has been proved to provide good synergistic effects in combination with either
83 pyrazinamide (PZA) or RIF, demonstrating a potential role in combination therapies (6).
84 With cytochrome *bd* inactivation, TB47 holds a significant bactericidal potential (6). We
85 revealed that TB47 exerted high bactericidal and sterilizing activity and corresponding
86 remarkable treatment-shortening effect in mice infected with *Mycobacterium ulcerans*
87 which lacks cytochrome *bd* activity naturally (5,7). It has also shown a very good
88 synergistic activity with clofazimine (CLF) against *Mycobacterium abscessus* and *M.*
89 *tuberculosis* both *in vitro* and *in vivo* (10,11), and even played a remarkable role in
90 shortening MDR-TB treatment duration from ≥ 9 to 5 months in a well-established
91 murine model of TB (11). CLF competes with menaquinone and kills bacteria by
92 generating lethal levels of reactive oxygen species (12), and regimens containing CLF
93 and cytochrome $bc_1$ inhibitors or other electron transport chain-targeting drugs provide

94 enhanced killing of both replicating and non-replicating *M. tuberculosis* (13–15),
95 suggesting that dual or multiple targeting of the electron transport chain may be a novel
96 approach to enhanced killing of mycobacteria (7,10).

97 Considering the extensive resistance to FQs (16) and PZA (17–19) by DR-TB, the
98 serious side effects and inconvenience associated with injectable drugs, as well as the fact
99 that the patent-expiring linezolid (LZD) showed a very good activity against DR-TB in
100 clinical use (20), we evaluated the effect of partially or totally replacing them with LZD
101 in drug combinations containing TB47 + CLF as a block to study their benefits in new
102 regimens and to explore the possibility of developing a novel, fully oral pan-TB regimen.

## 103 RESULTS

104 **Establishment of *M. tuberculosis* infection in female BALB/c mice.** The scheme of the
105 experimental design is shown in Table 1. On the day after infection (Day -15), *M.*
106 *tuberculosis* H37Rv reached a cell density of 4.64 ± 0.19 mean $\log_{10}$ CFU (colony-
107 forming unit) in the lungs. At the time of treatment initiation (Day 0), the *M. tuberculosis*
108 burden increased to 8.18 ± 0.14 mean $\log_{10}$ CFU, demonstrating that a heavy infection
109 was established in the lungs. All nine untreated mice (Table 1) succumbed to TB
110 infection between day 22 and day 25 post-infection.

111 **Bactericidal activities of the test regimens.** Details of lung CFU counts obtained at
112 various time points are presented in Table 2. While two of five mice in the NCTZ group,

and only one of five mice in the LNCTZ group were culture negative (Table 2), all mice treated with other regimens remained culture positive after 2.5 months of treatment. The mean $\log_{10}$ CFU counts in the lungs declined significantly in all groups during the course of treatment (Table 2, Figure 1). LZD was used only for 3 months due to side effects (11). Addition of levofloxacin (LVX) to the AEZCT regimen resulted in stronger bactericidal activity compared to the AEZCT regimen alone ($P = 0.0003 < 0.001$) (Figure 1a). In contrast, contribution of LVX to the bactericidal activities of NCT and NCTZ was not significant ($P > 0.05$) (Figure 1b). However, there were significant differences between PZA-containing (NCTZ and LNCTZ) and corresponding PZA-lacking regimens (NCT and LNCT, $P < 0.0001$ and $P < 0.001$, respectively) (Figure 1b). Compared to ALEZCT, the stronger regimen containing amikacin (AMK), the injectable drug, NCTZ showed better bactericidal activity ($P = 0.04 < 0.05$), NCT showed less bactericidal activity ($P = 0.02 < 0.05$), LNCT and LNCTZ showed no difference ($P = 0.097$, $P = 0.65$, respectively) (Table 2).

**Relapse rates after treatment cessation.** *M. tuberculosis*-infected mice were subjected to various duration of treatment using various combination regimens, after which a number of mice were held for 3.5 months followed by two weekly immunosuppression treatment with dexamethasone (DXM) prior to euthanasia and detection of *M. tuberculosis* in lungs for relapse (Table 1). Treatment with 2ALEZCT/2LEZC for 4 months resulted in a 13.33 % (2/15) relapse rate, which later reduced to 0 % (0/15) with

133 another month of LEZC (Table 3). These results are almost the same with those from our
134 previous study (11). In contrast, treatment with 2AEZCT/3EZCT for 5 months and
135 2AEZCT/4EZCT for 6 months yielded a 33.33 % (5/15) and 0 % (0/15) relapse rates,
136 respectively (Table 3), which indicated that LVX played a role in shortening the treatment
137 duration in ALEZCT combination, though it did not show a sharp activity in lowering the
138 *M. tuberculosis* burden in lungs during the 2.5 months of treatment as mentioned above.
139 Similarly, 3LNCT/2LCT for 5 months achieved 0% relapse rate, a month earlier than
140 3NCT/3CT did, which also suggested that LVX has played a role in the LNCT
141 combination. Unexpectedly, after 4 and 5 months of treatment, both 3NCTZ/2CTZ- and
142 3LNCTZ/2LCTZ-treated mice showed 0 % (0/15) relapse rates (Table 3), which could
143 not provide evidence of benefit of LVX in LNCTZ combination. This was consistent with
144 the lack of difference in their bactericidal activities. We speculate that the actual cure
145 time could be even shorter than 4 months for LNCTZ and NCTZ groups. Adding PZA
146 into NCT significantly ($P < 0.0001$) shortened the treatment duration as 3NCTZ/2CTZ
147 achieved 0 % (0/15) relapse rate at least 2 months earlier than 3NCT/4CT, which was
148 accordant to the bactericidal activities of these two regimens. We could not provide
149 evidence of benefit of PZA in the combination 3LNCTZ/2LCTZ as we had no cohort of
150 mice relapsed in either 3LNCTZ/2LCTZ or 3LNCT/4LCT at designed time points. All
151 four oral regimens could achieve 0 % (0/15) relapse rate in 4 to 6 months, which were
152 shorter than or equal to the treatment duration of AMK-containing regimens (5 to 6

153 months). This indicated that LZD may be able to replace ALE or ALEZ in the control
154 regimen 2ALEZCT/3LEZC and still provide equal or even better outcome.

155 **DISCUSSION**

156 Potency of the standard short-course regimen consisting of first-line drugs (RIF +
157 isoniazid + PZA + ethambutol (EMB)) for drug-susceptible TB requires at least 6
158 months of treatment. However, for DR-TB, the duration of treatment is even longer and
159 treatment options are limited. Emergence of DR-TB, therefore, poses a significant threat
160 to individual patient management and global TB control efforts. For this reason, a
161 plethora of safer and accessible novel regimens that could shorten the duration of DR-TB
162 treatment are urgently needed (21), one of which is the recent FDA-approved BPaL.

163 Injectable drugs are not recommended for TB treatment due to their toxicity, poor
164 efficacy and causation of irreversible adverse effects, and may regularly need to be taken
165 at healthcare facilities. The WHO suggests the phasing out of injectable drug-containing
166 regimens and adoption of a shorter all-oral bedaquiline-containing regimen for treatment
167 of MDR/RR-TB (22). All-oral regimens, therefore, as opposed to injectable drug-
168 containing regimens, are a preferred alternative for TB treatment as shown by improved
169 clinical outcomes. It has become quite important to study the synergistic activities of
170 novel drugs/compounds with no cross-resistance with other anti-TB drugs as activities of
171 some compounds may be determined by efficacies of their companion drug(s) (23).

172 TB47 is an antimycobacterial candidate that has a good safety profile and ideal

173 pharmacokinetic parameters (5,6), as well as good synergistic effects with other TB drugs
174 (6,10). We used the Bangladesh regimen + TB47 (ALEZCT) from our previous study
175 (11) as a positive control here, in which we further confirmed the highly synergistic
176 activity of TB47 + CLF in shortening MDR-TB treatment duration to ≤ 5 months with
177 no relapse in the murine TB model. The Bangladesh regimen is not commonly used in
178 some places partly due to high prevalence of resistance to FQs and PZA in DR-TB
179 patients (17,24), especially in countries with high TB burden (25,26), for example, China,
180 and their roles in the regimen have not been fully elucidated in an animal model.
181 Therefore, considering the severity of resistance to FQs (16) and PZA (17–19) and the
182 serious side effects and inconvenience associated with injectable drugs, we evaluated the
183 effect of partially or totally replacing them in the drug combinations with the repurposed
184 LZD to study their benefits in the new regimens based on LZD + CLF + TB47 as a
185 backbone.

186 Rather than holding cohorts of mice for six months prior to relapse assessment as
187 described before (11), here, mice were held for 3.5 months followed by two weekly
188 immunosuppression treatment with DXM and the relapse results were comparable to our
189 previous study (11). We propose that four months, including immunosuppression after
190 treatment cessation, are long enough to monitor relapse, though the half-life of CLF is
191 long and may interfere with relapse evaluation.

192 Here, we incorporated TB47 + CLF into all test regimens to further study regimens

193 containing this suite of compounds. The regimen containing NCT showed very good
194 bactericidal and sterilizing activities (Table 2 and Table 3), which may cure TB in 6
195 months and could possibly form an all-oral pan-TB regimen for any form of DR-TB.
196 Inclusion of PZA in a combination regimen has been thought to even further shorten the
197 course of TB treatment provided the infecting strain remains PZA-susceptible (27). Based
198 on NCT, adding PZA could sharply shorten the duration further by two months or more
199 (Table 3). This points to the remarkable role of PZA in combination with NCT, and PZA
200 should be used when necessary.

201 As for LVX, it exhibited both bactericidal and sterilizing benefits in the regimen
202 2ALEZCT/3LEZCT over 2AEZCT/4EZCT (Figure 1, Table 2, Table 3). However, both
203 the bactericidal and sterilizing activities of NCT/3CT and 3LNCT/3LCT, which
204 contained NCT were indifferent ($P > 0.05$), even though they showed 6.67% and 0%
205 relapse rates, respectively after 5 months of treatment. Adding LVX into NCT-containing
206 regimens used here had only a limited or even no additive effect. Our data supports that
207 notion that LVX and other FQs may be removable in such regimens. However, if LVX
208 should be withdrawn from the Bangladesh regimen containing TB47 (ALEZCT),
209 administration of the regimen would be subject to an extension by one month.

210 Because CLF + LZD + TB47 were prepared and administered together in this
211 experiment, we speculate that in all LZD-containing regimens, had the administration of
212 LZD been separated from administration of its companion drugs by at least 4 hours (27),

213 their bactericidal effects might have been better than what was observed here as LZD
214 affects the absorption of companion agents (28).

215 It is noticeable that "BPaL" has shown remarkably promising effect against both
216 MDR- and XDR-TB in a phase III clinical trial (NCT02333799) by curing > 90% DR-TB
217 patients in 6 months, though most patients have had a reduction in dose or interruption of
218 LZD during treatment. However, side effects of the drug have been shown to be
219 dependent on dose and duration of treatment and were manageable by withdrawal of
220 LZD or interruption and resumption of treatment without sabotaging the efficacy of the
221 regimen (20). Those justify the withdrawal of LZD from LZD-containing regimens after
222 the first three months of treatment in this study. Besides the side effects, cost and
223 accessibility of the "BPaL" regimen is also a cause for concern by many TB patients.

224 In conclusion, we report potentially effective all-oral regimens based on TB47 + LZD
225 + CLF, which could achieve complete sterilization after 6 months of treatment and even
226 4 months with addition of PZA in a mouse TB model. The benefit of adding LVX was not
227 quite obvious, especially in the NCT-based regimens, likely because its activity was
228 masked by other companion agents. Though it is too early to infer that the early
229 bactericidal and sterilizing potentials of the regimens in this study will necessarily
230 translate directly to human TB, the promising potentials of the regimens warrant further
231 studies to ascertain their clinical applicability in treatment of MDR- or even XDR-TB.

232 ## MATERIALS AND METHODS

233 **Ethical approval.** All animal procedures were approved by the Institutional Animal Care
234 and Use Committee of the Guangzhou Institutes of Biomedicine and Health, Chinese
235 Academy of Sciences (#2018053).

236 **Mycobacterial strains and growth conditions.** A mouse-passaged *M. tuberculosis*
237 H37Rv strain (ATCC 27294) preserved at -80ºC was subcultured in Middlebrook 7H9
238 broth (Difco, Detroit, MI, USA) supplemented with 10% oleic acid-albumin-dextrose-
239 catalase enrichment medium (BBL, Sparks, MD, USA), 0.2% glycerol, and 0.05% Tween
240 80 at 37ºC. Broth cultures of *M. tuberculosis* at the logarithmic phase with $OD_{600}$
241 between 0.8 and 1.0 were used for the infection.

242 **Antimicrobials.** All drugs used in the study were purchased from Meilun bio (Dalian,
243 China) except for TB47 and DXM. TB47 was synthesized and supplied by Shanghai
244 Abotchem Co. Ltd (Shanghai, China) with a purity of ≥ 95%. DXM was purchased from
245 Sigma-Aldrich (St. Louis, MO, USA). AMK and DXM were dissolved in sterile
246 phosphate-buffered saline (PBS). LVX, EMB, and PZA were dissolved in distilled water.
247 LZD, CLF, and TB47 were suspended in 0.4% sodium carboxymethyl cellulose
248 (Solarbio, Beijing, China). All drug solutions/suspensions were prepared to deliver the
249 drug(s) and dose(s) in a total volume of 0.2 mL per gavage or 0.1 mL per injection, based
250 on the average mouse body weight of 20 g. Drug solutions and suspensions were

251 prepared weekly and stored at 4ºC prior to use.

252 **Aerosol infection and determination of bacterial burden.** Five to six weeks old female
253 BALB/c mice were purchased from Charles River Laboratories (Beijing, China).
254 Following several days of acclimatization, 362 mice were infected with *M. tuberculosis*
255 H37Rv at a high dose by an inhalation exposure system (Glas-Col, Terre Haute, IN,
256 USA). The mice were block randomized into treatment groups and timed sacrifice
257 cohorts before the start of treatment. Nine mice with 3 mice from each infection run were
258 humanely sacrificed 1 day after infection (Day -15) and on the day of treatment initiation
259 (Day 0) to determine the CFU counts of bacteria implanted in the lungs and at the start of
260 treatment, respectively. *In vivo* bactericidal activities of regimens were measured by lung
261 CFU counts during treatment for each time point.

262 **Chemotherapy.** Drugs were prepared as previously described (11,27). The daily doses
263 (mg/kg) are as follows: AMK 100, LVX 300, EMB 100, PZA 150, CLF 25, LZD 100 and
264 TB47 50. The scheme is shown in Table 1. Fifteen days after infection, mice were treated
265 once daily, 5 days per week (from Monday to Friday). AMK was administered
266 subcutaneously, and other drugs were administered orally by gavage. LVX + EMB or
267 CLF + LZD + TB47 were prepared and administered together in a single dose. PZA was
268 prepared and administered alone. The lung CFU count for each mouse was determined as
269 scheduled. Mice used for relapse assessment were subcutaneously injected with DXM

270 (10 mg/kg) 3.5 months post-treatment cessation for immunosuppression. DXM was
271 administered again a week later, after which the mice were kept for a week prior to
272 sacrifice.

273 **Assessment of treatment efficacy.** Efficacy was assessed on the basis of lung CFU
274 counts at selected time points during treatment (a measure of bactericidal activity) and
275 the proportion of mice with culture-positive relapse 4 months after treatment completion
276 (a measure of sterilizing activity). Lungs were dissected from the mice and homogenized
277 in 2.0 mL sterile PBS using glass tissue grinders. Undiluted as well as 10-fold serial
278 dilutions of the homogenates were prepared and cultured with a volume of 0.5 mL per
279 7H11 agar plate. Since CLF carryover can affect the growth of *M. tuberculosis*, lung
280 homogenates from CLF-containing groups were plated on 7H11 agar containing 0.4%
281 (weight/volume) activated charcoal to adsorb residual CLF (29). Plates were incubated
282 for 4 to 5 weeks at 37ºC before CFU counting. Relapses were assessed 4 months
283 (including two immunosuppressions) post-treatment cessation by equally plating the
284 homogenate of the whole lung on 4 plates. If ≥ 1 colony appeared, the mouse was
285 considered as relapse.

286 **Statistical analysis.** CFU counts (x) were log-transformed to $\log_{10}$ (x + 1) prior
287 statistical analyses, using 0.05 significance level and 95 % confidence interval.
288 Bactericidal activities of all regimens were compared by two-way analysis of variance

289 with Tukey's post-test to correct for multiple comparisons. Sterilizing activities of all the
290 regimens were analyzed by Fisher's exact test, adjusting for multiple comparisons.
291 GraphPad Prism version 8.0.2 (GrahPad, San Diego, CA) was used for all statistical
292 analyses.

## 293 ACKNOWLEDGMENTS

294 This work was supported by the National Mega-project of China for Innovative Drugs
295 (2019ZX09721001-003-003), by the National Natural Science Foundation of China
296 (NSFC,81973372, 21920102003), by Joint Research of the Russian Science Foundation-
297 NSFC Collaboration (21-45-00018 & 82061138019), by the Health Research Council of
298 New Zealand-NSFC Biomedical Collaboration Fund (20/1211 & 8206112800),the
299 Chinese Academy of Sciences Grants (154144KYSB20190005), the Grant (SKLRD-OP-
300 201919, SKLRD-OP-202113) from the State Key Laboratory of Respiratory Disease and
301 First Affiliated Hospital of Guangzhou Medical University. This work was sponsored by
302 Science and Technology Innovation Leader of Guangdong Province (2016TX03R095 to
303 TZ), the UCAS (to Y.B.) and "One Belt One Road" (to A.M.S.) Master Fellowship
304 Programs for international students, CAS-TWAS President's PhD Fellowship Program (to
305 G.C.) for international students, and the Postdoctoral Fellowship from the University of
306 Chinese Academy of Sciences (to H.M.A.H). The funders had no role in study design,
307 data collection and analysis, decision to publish, or preparation of the manuscript.

## References


1. World Health Organization (WHO). 2020. Global Tuberculosis Report. Available at: https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf

2. World Health Organization. 2019. WHO Consolidated guidelines on drug-resistant tuberculosis treatment. Available at: https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf?ua=1

3. World Health Organization (WHO). 2019. Global Tuberculosis Report. Available at: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf

4. Tang J, Wang B, Wu T, Wan J, Tu Z, Njire M, Baojie W, Scott GF, Tianyu Z, Xiaoyun L, Ke D. 2015. Design, Synthesis, and Biological Evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides as Novel Antitubercular Agents. ACS Med Chem Lett. 6(7):814–8.

5. Liu Y, Gao Y, Liu J, Tan Y, Liu Z, Chhotaray C, Huofeng J, Zhili L, Gift C, Shuai W, Gaelle M, Islam MM, Hameed HMA, Xingshan C, Changwei W, Xinjie L, Shouyong T, Tianyu Z. 2019. The compound TB47 is highly bactericidal against *Mycobacterium ulcerans* in a Buruli ulcer mouse model. Nat Commun 10(1):1–9. https://dx.doi.org/10.1038/s41467-019-08464-y

326 6. Lu X, Williams Z, Hards K, Tang J, Cheung CY, Aung HL, Bangxing W, Zhiyong L,
327 Xianglong H, Anne L, Lisa W, Courtney H, Xiantao Z, Zhe W, Kyu R, Ke D,
328 Zhang T, Cook GM. 2019. Pyrazolo[1,5- a]pyridine Inhibitor of the Respiratory
329 Cytochrome bcc Complex for the Treatment of Drug-Resistant Tuberculosis. ACS
330 Infect Dis. 2019;5(2):239–49.

331 7. Lee BS, Hards K, Engelhart CA, Hasenoehrl EJ, Kalia NP, Mackenzie JS, Sviriaeva E,
332 Chong SMS, Manimekalai MSS, Koh VH, Chan J, Xu J, Alonso S, Miller MJ,
333 Steyn AJC, Gruber G, Schnappinger D, Berney M, Cook GM, Moraski GC, Pethe
334 K. 2021. Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant
335 *Mycobacterium tuberculosis*. EMBO Mol Med 13: e13207.

336 8. Kalia NP, Hasenoehrl EJ, Ab Rahman NB, Koh VH, Ang ML, Sajorda DR, Hards K,
337 Grüber G, Alonso S, Cook GM, Berney M, Pethe K. 2017. Exploiting the synthetic
338 lethality between terminal respiratory oxidases to kill *Mycobacterium tuberculosis*
339 and clear host infection. Proc Natl Acad Sci U S A 114:7426-743.

340 9. Gao Y, Hameed HMA, Liu Y, Guo L, Fang C, Tian X, Liu Z, Wang S, Lu Z, Islam
341 MM, Zhang T. 2020. Ultra-short-course and intermittent TB47-containing oral
342 regimens produce stable cure against Buruli ulcer in a murine model and prevent
343 the emergence of resistance for *Mycobacterium ulcerans*, Acta Pharm. Sin. B.,
344 S2211-3835(20)30796-6. https://doi.org/10.1016/j.apsb.2020.11.007.

10. Liu Y, Tan Y, Islam MM, Cao Y, Lu X, Zeng S, Hameed HMA, Zhou P, Cai X, Wang S, Mugweru JN, Zhang G, Yin H, Liu J, Nuermberger E, Zhang T. 2020. Assessment of clofazimine and TB47 combination activity against *Mycobacterium abscessus* using a bioluminescent approach. Antimicrob Agents Chemother. 2020;64(3):1–13.

11. Yu W, Chiwala G, Gao Y, Liu Z, Sapkota S, Lu Z, Guo L, Khan SA, Zhong N, Zhang T. 2020. TB47 and clofazimine form a highly synergistic sterilizing block in a second-line regimen for tuberculosis in mice. Biomed Pharmacother. 131(2020)110782. https://doi.org/10.1016/j.biopha.2020.110782

12. Yano T, Kassovska-Bratinova S, Shin Teh J, Winkler J, Sullivan K, Isaacs A, Schechter NM, Rubin H. 2011. Reduction of clofazimine by mycobacterial type 2 NADH: Quinone Oxidoreductase: A pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem. 2011;286(12):10276–87.

13. Berube BJ, Parish T. 2018. Combinations of respiratory chain inhibitors have enhanced bactericidal activity against *Mycobacterium tuberculosis*. Antimicrob Agents Chemother. 2018;62(1):1–10.

14. Lamprecht DA, Finin PM, Rahman MA, Cumming BM, Russell SL, Jonnala SR, Adamson JH, Steyn AJC. 2016. Turning the respiratory flexibility of *Mycobacterium tuberculosis* against itself. Nat Commun 2016;7:1–14. Available

364 from: https://dx.doi.org/10.1038/ncomms12393

365 15. Berube BJ, Russell D, Castro L, Choi S-R, Narayanasamy P, Parish T. 2019. Novel
366 MenA inhibitors are bactericidal against *Mycobacterium tuberculosis* and
367 synergize with electron transport chain inhibitors. Antimicrob Agents Chemother
368 63:e02661-18. https://doi.org/10.1128/AAC.02661-18.

369 16. Ali S, Zeb MT, Masood N, Afzal MT. 2018. Prevalence of Pyrazinamide Resistance
370 in Khyber Pakhtunkhwa, Pakistan. Microb Drug Resist. 2018;00(00):1–5.
371 https://doi.org/10.1089/mdr.2017.0234

372 17. Hameed HMA, Tan Y, Islam M, Lu Z, Chhotaray C, Wang S, Zhiyong L, Cuiting F,
373 Shouyong T, Wing WY, Nanshan Z, Jianxiong L, Tianyu Z. 2020. Detection of
374 Novel Gene Mutations Associated with Pyrazinamide Resistance in Multidrug-
375 Resistant *Mycobacterium tuberculosis* Clinical Isolates in Southern China. Infect
376 Drug Resist 2020:13 217–227.

377 18. Shi J, Su R, Zheng D, Zhu Y, Ma X, Wang S, Li H, Sun D. 2020. Pyrazinamide
378 Resistance and Mutation Patterns Among Multidrug-Resistant *Mycobacterium*
379 *tuberculosis* from Henan Province. Infect Drug Resist 2020:13 2929–2941.

380 19. Kurbatova E V, Cavanaugh JS, Dalton T, Click ES, Cegielski JP. 2013. Epidemiology
381 of Pyrazinamide-Resistant Tuberculosis in the United States , 1999 – 2009. Clin

382 Infect Dis 2013;57(8):1081–93. DOI: 10.1093/cid/cit452

383 20. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM,
384 Egizi E, Moreira J, Timm J, McHugh TD, Wills GH, Bateson A, Hunt R, Van
385 Niekerk C, Li M, Olugbosi M, Spigelman M. 2020. Treatment of highly drug-
386 resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893–902.
387 doi:10.1056/NEJMoa1901814.

388 21. O'Brien RJ, Nunn PP. 2001. The need for new drugs against tuberculosis: Obstacles,
389 opportunities, and next steps. Am J Respir Crit Care Med. 2001;163(5):1055–8.

390 22. World Health Organization. 2019. Rapid Communication : Key changes to the
391 treatment of drug-resistant tuberculosis. Available at:
392 https://www.who.int/tb/publications/2019/WHO_RapidCommunicationMDR_TB2
393 019.pdf?ua=1

394 23. Xu J, Li SY, Almeida DV., Tasneen R, Barnes-Boyle K, Converse PJ, Upton AM,
395 Mdluli K, Fotouhi N, Nuermberger EL. 2019. Contribution of pretomanid to novel
396 regimens containing bedaquiline with either linezolid or moxifloxacin and
397 pyrazinamide in murine models of tuberculosis. Antimicrob Agents Chemother.
398 2019;63(5):1–14.

399 24. Hameed HMA, Tan Y, Islam MM, Guo L, Chhotaray C, Wang S, Liu Z, Gao Y, Tan S,

400 Yew WW, Zhong N, Liu J, Zhang T. 2019. Phenotypic and genotypic
401 characterization of levofloxacin- and moxifloxacin-resistant *Mycobacterium*
402 *tuberculosis* clinical isolates in southern China. J Thorac Dis. 2019;11(11):4613–
403 25. https://dx.doi.org/10.21037/jtd.2019.11.03.

404 25. Singh PK, Jain A. 2019. Limited Scope of Shorter Drug Regimen for MDR TB
405 Caused by High Resistance to Fluoroquinolone. Emerg Infect Dis
406 2019;25(9):1760–2. https://doi.org/10.3201/eid2509.190105.

407 26. Singh N, Kumar P, Singh U, Garg R, Jain A. 2021. Fluroquinolone drug resistance
408 among MDR-TB patients increases the risk of unfavourable interim
409 microbiological treatment outcome : An observational study. J Glob Antimicrob
410 Resist 24(2021)40–44. https://doi.org/10.1016/j.jgar.2020.11.011.

411 27. Tasneen R, Betoudji F, Tyagi S, Li S-Y, Williams K, Converse PJ, Dartois V, Yang T,
412 Mendel CM, Mdluli KE, Nuermberger EL. 2016. Contribution of oxazolidinones
413 to the efficacy of novel regimens containing bedaquiline and pretomanid in a
414 mouse model of tuberculosis. Antimicrob Agents Chemother 60:270 –277.
415 doi:10.1128/AAC.01691-15.

416 28. Williams KN, Brickner SJ, Stover CK, Zhu T, Ogden A, Tasneen R, Tyagi S, Grosset
417 GH, Nuermberger EL. 2009. Addition of PNU-100480 to First-Line Drugs
418 Shortens the Time Needed to Cure Murine Tuberculosis. Am J Respir Crit Care

Med 2009(180) 371–376. doi:10.1164/rccm.200904-0611OC.

29. Tyagi S, Ammerman NC, Lia SY, Adamson J, Converse PJ, Swanson RV, Almeida DV, Grosset JH. 2015. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proc Natl Acad Sci U S A 112(3) 869–874. doi:10.1073/pnas.1416951112.

Table 1. Scheme of the experiment.

| | Number of mice used to determine lung CFU counts at the given time points | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Regimen[a] | D-15 | D0 | M1 | M1.5 | M2 | M2.5 | M4 | M5 | M6 | M7 | Total |
| Untreated | 9 | 9 | 9 | | | | | | | | 27 |
| 2ALEZCT/3LEZCT | | | | 5 | 5 | 5 | (15)[b] | (15) | | | 45 |
| 2AEZCT/4EZCT | | | | 5 | 5 | 5 | (15) | (15) | (15) | | 60 |
| 3NCT/4CT | | | 5 | 5 | 5 | 5 | | (15) | (15) | (15) | 65 |
| 3NCTZ/2CTZ | | | 5 | 5 | 5 | 5 | (15) | (15) | | | 50 |
| 3LNCT/4LCT | | | 5 | 5 | 5 | 5 | | (15) | (15) | (15) | 65 |
| 3LNCTZ/2LCTZ | | | 5 | 5 | 5 | 5 | (15) | (15) | | | 50 |
| Total | 9 | 9 | 29 | 30 | 30 | 30 | 60 | 90 | 45 | 30 | 362 |

[a] Numbers in the drug regimen descriptions indicate the number of months (4 weeks/month) for which the drug combination was administered. A, amikacin; L, levofloxacin; E, ethambutol; Z, pyrazinamide; C, clofazimine; N, linezolid; T, TB47. All the drugs were administered once a day, 5 days per week, at the following doses (mg/kg): A 100, L 300, E 100, Z 150, C 25, N 100 and T 50. A was administered subcutaneously and others were orally.

D-15, one day after infection with *M. tuberculosis* H37Rv.

D0, day of treatment initiation.

M1, one month after treatment initiation, and so on.

[b] Numbers in parentheses indicate the number of mice that were held for 4 months after treatment completion before being killed for relapse assessment.

Table 2. Lung CFU counts during the course of experiment.

| Regimen[a] | D-15 | D0 | M1 | M1.5 | M2 | M2.5 |
|---|---|---|---|---|---|---|
| Untreated | 4.64 ± 0.19 | 8.18 ± 0.14 | | | | |
| 2ALEZCT/3LEZCT | | | | 2.10 ± 0.25 | 1.32 ± 0.61 | 0.76 ± 0.63 |
| 2AEZCT/4EZCT | | | | 2.57 ± 0.08 | 2.12 ± 0.16 | 1.34 ± 0.39 |
| 3NCT/4CT | | | 4.53 ± 0.11 | 2.25 ± 0.19 | 1.95 ± 0.21 | 1.31 ± 0.54 |
| 3NCTZ/2CTZ | | | 3.67 ± 0.34 | 1.42 ± 0.48 | 0.95 ± 0.21 | 0.59 ± 0.59[b] |
| 3LNCT/4LCT | | | 4.41 ± 0.39 | 2.40 ± 0.24 | 1.60 ± 0.46 | 1.27 ± 0.48 |
| 3LNCTZ/2LCTZ | | | 3.56 ± 0.20 | 1.71 ± 0.40 | 0.91 ± 0.51 | 0.93 ± 0.67[c] |

[a] Numbers in the drug regimen descriptions indicate the number of months (4 weeks/month) for which the drug combination was administered. A, amikacin; L, levofloxacin; E, ethambutol; Z, pyrazinamide; C, clofazimine; N, linezolid; T, TB47. All the drugs were administered once a day, 5 days per week, at the following doses (mg/kg): A 100, L 300, E 100, Z 150, C 25, N 100 and T 50. A was administered subcutaneously and others were orally.

[b] Two of five mice were culture negative.

[c] One of five mice was culture negative.

D-15, one day after infection with *M. tuberculosis* H37Rv.

D0, day of treatment initiation.

M1, one month after treatment initiation, and so on.

Results are presented as $Log_{10}$ CFU per lung ± standard deviation.

Table 3. Proportion of mice relapsing after treatment completion.

| Duration of treatment (months) | Regimen[a] | No. of culture-positive mice/total No. of mice (% of culture-positive)[b] |
|---|---|---|
| 4 | 2ALEZCT/3LEZCT | 2/15 (13.33%) |
| | | [4, 51][c] |
| | 2AEZCT/4EZCT | 5/15 (33.33%) |
| | | [76, 88, 180, 550, 410][c] |
| | 3NCTZ/2CTZ | 0/15 (0%) |
| | 3LNCTZ/2LCTZ | 0/15 (0%) |
| 5 | 2ALEZCT/3LEZCT | 0/15 (0%) |
| | 2AEZCT/4EZCT | 5/15 (33.33%) |
| | | [291, 161, +++, +++, +++][c] |
| | 3NCT/4CT | 1/15 (6.67%) |
| | | [46][c] |

| | | |
|---|---|---|
| | 3NCTZ/2CTZ | 0/15 (0%) |
| | 3LNCT/4LCT | 0/15 (0%) |
| | 3LNCTZ/2LCTZ | 0/15 (0%) |
| 6 | 2AEZCT/4EZCT | 0/15 (0%) |
| | 3NCT/4CT | 0/15 (0%) |
| | 3LNCT/4LCT | 0/15 (0%) |
| 7 | 3NCT/4CT | 0/15 (0%) |
| | 3LNCT/4LCT | 0/15 (0%) |

[a] Numbers in the treatment regimen descriptions represent the number of months for which the drug combination was administered. Relapse was defined as ≥ one *M. tuberculosis* colony appeared on the plates spread with the entire lung homogenate 4 months after the indicated duration of treatment. Each lung homogenate was equally divided and plated on 4 plates.

[b] The proportion of mice with culture-positive relapse was determined by holding cohorts of mice for an additional 4 months after treatment completion.

[c] Values in brackets indicate the number of colonies from lung homogenates of mice with relapse after treatment completion.

+++ indicates too many to count.

458

459

460

461




462

463

464

465

466



**Figure 1. Bactericidal activities of the studied regimens as observed during the course of experiment.** (a) Adding LVX to AEZCT had a noticeable effect on its bactericidal activity. (b) Addition of LVX did not result in significant contribution to activities of any of the NCT-based regimens. However, addition of PZA resulted in significant differences between PZA-containing and PZA-lacking regimens. Incorporation of both LVX and PZA enhanced the activity of NCT, but the activity of NCT with PZA alone equals or even surpasses the activity of NCT with both LVX and PZA added. ns, not significant, $P > 0.05$; ***, $P < 0.001$; ****, $P < 0.0001$. D -15, Day -15; M1, month 1, and so on.